Main content

News

• DATA ON HEXVIX®/CYSVIEW® TO BE PRESENTED AT AMERICAN UROLOGICAL ASSOCIATION, SAN DIEGO, USA

  06.05.2013

• Results for the first quarter 2013

  25.04.2013

• Discovery Channel features Cysview® - The Health Heros program features advancements in detection of bladder cancer

  16.04.2013

• Blue Light Cystoscopy with Cysview® demonstrates cost-effectiveness

  22.04.2013

• Updated European Association of Urology Guidelines Strengthen Recommendation on Use of Hexvix®

  Recognizes Benefit of Hexvix in Reducing Recurrence Rate and Improving Time to Recurrence of Bladder Cancer
  03.04.2013

• POSITIVE FINAL RESULTS OF PHASE 2B CEVIRA® STUDY

  Results demonstrate significant and sustained efficacy in treating human papilloma virus and precancerous lesions of the cervix.
  10.04.2013

• Presentation of final results of phase 2b Cevira® study

  11.04.2013

• NEW META-ANALYSIS CONFIRMING THE CLINICAL BENEFIT OF HEXVIX®-GUIDED BLUE LIGHT CYSTOSCOPY PRESENTED AT EAU, MILAN

  18.03.2013

• POSITIVE CEVIRA® DATA PRESENTED AS LATE BREAKER AT 2013 SOCIETY OF GYNECOLOGIC ONCOLOGY ANNUAL MEETING ON WOMEN'S CANCER

  11.03.2013

• Wall Street Journal Features Visonac Development

  11.03.2013

• PHASE 2 DATA ON VISONAC® IN ACNE WILL BE PRESENTED AT THE AMERICAN ACADEMY OF DERMATOLOGY 71ST ANNUAL MEETING

  01.03.2013

• Results fourth quarter and full year 2012

  28.02.2013

• Presentation of the fourth quarter and the full year 2012 report

  26.02.2013

• PHOTOCURE ANNOUNCES EXPANSION OF HEXVIX® INDICATION

  15.02.2013

• PHOTOCURE ANNOUNCES PAYMENT RECEIVED FOR LUMACAN® DEVELOPMENT

  02.01.2013

• PHOTOCURE ANNOUNCES POSITIVE RESULTS OF CEVIRA® STUDY

  RESULTS DEMONSTRATE SIGNIFICANT EFFICACY IN TREATMENT OF LESIONS AND ONCOGENIC HUMAN PAPILLOMA VIRUS IN PATIENTS WITH PRECANCEROUS LESIONS OF THE CERVIX
  05.12.2012

• Photocure to present at DNB Markets 2012 Nordic Healthcare Conference

  03.12.2012

• Photocure presentation at Jefferies 2012 Global Healthcare Conference

  14.11.2012

• Presentation of third quarter and first nine months 2012 results

  26.10.2012

• Results third quarter and first nine months 2012

  Oslo, Norway, 26 October 2012: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, today announces its results for the third quarter and the first nine months 2012, for the period ended 30 September 2012.
  26.10.2012

• Presentation of the third quarter 2012 report

  23.10.2012

• Photocure to Exit Allumera Business

  Oslo, Norway, 1 October 2012: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces today that it has made the strategic decision to exit its Allumera® cosmetic dermatology business in the US.
  01.10.2012

• Presentation of second quarter and first half 2012 results

  24.08.2012

• Results second quarter and first half 2012

  Oslo, Norway, 24 August 2012: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, today announces its results for the second quarter and the first half year 2012, for the period ended 30 June 2012.
  24.08.2012

• Interview: Simplifying Existing Procedure Eases Market Penetration for Photocure

  President and CEO Kjetil Hestdal discusses the company's photodynamic technology harnessed in Hexvix® and Allumera®. Hexvix®, branded as Cysview® in the U.S., aids in cystoscopy procedures for bladder cancer.
  06.07.2012

• Photocure strengthens the management team

  Announces appointment of Chief Finance Officer
  05.07.2012

• Final transition milestone for Hexvix® achieved

  A total of EUR 5 million in manufacturing milestones achieved to date
  18.06.2012

• Photocure announces positive results of phase 2b study evaluating Visonac® in acne

  Results demonstrate a significant reduction in inflammatory lesions and a significant improvement in overall acne severity.
  31.05.2012

• Data presented shows that Hexvix® cystoscopy significantly improves time to recurrence of bladder cancer

  Photocure to present data on impact of Hexvix®/Cysview® on long term recurrence rates at American Urological Association annual meeting, Atlanta, GA, USA. The results indicates that Hexvix cystoscopy significantly improves time to recurrence of bladder cancer.
  22.05.2012

• Enhanced market access to Cysview® in the US market

  
  Photocure announces FDA approval of upgraded Karl Storz blue light cystoscope for use with Cysview. This will significantly enhance the market access to Cysview in the US market.
  07.05.2012

• Announcement of the 1st Quarter Report 2012

  26.04.2012

• Photocure launches new corporate website

  Photocure has recently launched the new corporate website. It is a flexible and commercial showcase for Photocure’s validated success stories, based on the Photocure Technology™.
  20.04.2012

• Photocure achieves milestone triggering payment of €750,000

  Photocure has achieved the third and final manufacturing transition milestone from Ipsen, its new strategic partner for commercializing Hexvix® worldwide, excluding the US and Nordic region. This triggers a payment of EUR 750 thousand.
  11.04.2012

• Cevira® is easy to administer and shows encouraging early efficacy results

  The encouraging results from the Cevira® study are being presented today at the American Society of Colposcopy and Cervical Pathology (ASSCP) in San Francisco by Dr. Mark Einstein, Montefiore Medical Center, NY. Cevira® represents a breakthrough technology that integrates the drug and light source into a compact, single-use disposable device, for the treatment of human papilloma virus (HPV) associated diseases of the cervix.
  15.03.2012

• Photocure achieves milestone triggering payment of € 1.5 million

  Photocure announces today the achievement of the second manufacturing transition milestone from Ipsen, its new strategic partner for commercializing Hexvix® worldwide, excluding the US and Nordic region. This triggers a payment of EUR 1.5 million.
  05.03.2012

• Hexvix® improves bladder cancer free survival - data to be presented at the EAU congress

  Photocure and Ipsen to co-sponsor two symposia on bladder cancer management. Data on impact of Hexvix® on long term recurrence rates to be prestented at European Association of Urology (EAU) Congress, Paris
  24.02.2012

• Photocure’s partner Ipsen announces 4Q 11 Hexvix® sales in Germany and Italy

  02.02.2012

• Photocure Announces Transfer of Marketing Authorisation for Cysview® in the USA

  30.12.2011

• Photocure announces the achievement of the first transition milestone of Eur 2.0 million for Hexvix®

  11.10.2011

• Photocure announces new commercial strategy for Hexvix®, the innovative product for improved detection of bladder cancer

  • Strategic collaboration with Ipsen for marketing rights in Europe and the rest of the world except Nordics and the US • Photocure to commercialise the product directly in the US market
  27.09.2011

• Photocure initiates enrollment into phase II trial of Visonac® for treatment of moderate to severe acne

  18.07.2011

• Photocure Launches Allumera® A New, Dynamic Cosmetic For Achieving Timeless Skin

  Allumera Represents The First In A New Class Of Photodynamic Cosmetics
  22.06.2011

• Photocure initiates enrollment into phase II trial of Cevira® for cervical HPV infection

  First study to evaluate optimal dose of novel integrated drug-delivery device First novel therapeutic treatment option for highly prevalent cervical HPV infections and precancerous lesions
  22.06.2011

• Hexvix®/Cysview™ demonstrates long term benefit

  12.05.2011

• British Journal of Urology publishes paper on Hexvix®

  Demonstrates significant reduction in recurrence of bladder cancer
  23.03.2011

• Bladder cancer: Photodynamic diagnosis can improve surgical outcome

  30.11.2010

• Photocure announces positive preliminary results from the Allumera™ consumer trial

  Allumera™ shows significant improvements in appearance of skin compared to light
  29.11.2010

• Photocure signs agreement with Salix Pharmaceuticals for Lumacan™

  20.10.2010

• New publication on Hexvix® demonstrating that Hexvix® guided fluorescence cystoscopy reduces recurrence in patients with non-muscle invasive bladder cancer

  05.10.2010

• Photocure announces successful Phase II results for Cevira™

  04.10.2010

• Photocure establishes US subsidiary to build speciality dermatology business

  04.08.2010

• Photocure announces US approval of Cysview™ for detection of bladder cancer

  30.05.2010

• Photocure announces results from phase II study in acne with Visonac™

  28.05.2010

• Expert panel recommends the use of Hexvix®-cystoscopy

  21.04.2010

• Hexvix® receives reimbursement approval in Germany

  13.01.2010

• Photocure received positive response from FDA on the New Drug Application (NDA) for Hexvix® for detection of bladder cancer

  31.12.2009

• FDA Advisory Committee voted favourably to Hexvix® application in USA

  18.12.2009

• Photocure granted patent in Europe and Russia for Visonac™ in the treatment of acne

  26.11.2009

• Presentations held at Photocure ASA's Capital Markets Day

  03.11.2009

• Photocure divests Metvix® to Galderma for EUR 51 million

  07.10.2009

• Hexvix® cystoskopi finner mer kreft og gir mindre tilbakefall

  11.06.2009

• Hexvix® cystoscopy detects more cancer and reduces recurrence

  11.06.2009

• Presentation of Cevira® Phase 2b Results

  05.12.2012